Zrepag MF 1mg/500mg Tablet
By Zrepag MF
Rx
10 Tablet in a Strip

Composition
Repaglinide(1mg) + Metformin(500mg)

Manufacturer - Daylon Healthcare
715, Gold Crest business center, L.T road, Borivali-W, Mumbai 400092

Expires on or after
July, 2026

liver
When using Zrepag MF 1mg/500mg Tablet, caution should be taken in patients with liver disease. It may be necessary to adjust the dose of the medication, so it is important to consult your doctor before starting treatment. For patients with mild to moderate liver disease, Zrepag MF 1mg/500mg Tablet is typically initiated at a low dose to ensure safety. However, the use of this medication is not advised for patients with severe liver disease. Make sure to discuss your liver condition with your healthcare provider before taking Zrepag MF 1mg/500mg Tablet.

kidney
Zrepag MF 1mg/500mg Tablet requires caution in patients with kidney disease. Dosage adjustment might be necessary, so consult your doctor. Avoid using Zrepag MF 1mg/500mg Tablet in severe kidney disease. Regular kidney function tests are recommended during treatment.

alcohol
It is unsafe to drink alcohol while taking Zrepag MF 1mg/500mg Tablet.

driving
If you experience symptoms of low or high blood sugar while using Zrepag MF 1mg/500mg Tablet, avoid driving as it may affect your ability to drive safely.

pregnancy
Zrepag MF 1mg/500mg Tablet should be used with caution during pregnancy. Limited human studies suggest potential harm to the baby based on animal studies. Your doctor will evaluate the benefits and risks before prescribing. Kindly consult your doctor.

breastfeeding
Zrepag MF 1mg/500mg Tablet is likely safe during breastfeeding based on limited human data. The drug does not appear to pose a significant risk to the baby.
| Habit Forming | No |
| Chemical Class | - |
| Therapeutic Class | ANTI DIABETIC |
| Action Class | - |
₹140
Inclusive of all taxes
Content verified by

Dr. Gowri Kulkarni
MBBS - General Medicine, DNB - Psychiatry, MRCGP [INT] Family Medicine, BSIC (BACP)
Last update on 11-Feb-2025
